Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07638371 · ClinicalTrials.gov registry record · Phase 1
FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT07638371: Recruiting Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT07638371 is a Phase 1 study that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07638371, a Phase 1 study, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of MSK-TCR5 in participants with advance solid tumor cancer that has a KRAS, HRAS, or NRAS G12D mutation.
Interventions
- BIOLOGICAL MSK-TCR5
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2026-06-09 |
| Est. Completion | 2030-06-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07638371
The ClinicalTrials.gov registry entry for NCT07638371 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MSK-TCR5 is the first listed.
NCT07638371 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07638371 about?
NCT07638371 is a clinical study titled "FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers". The purpose of this study is to test the safety of MSK-TCR5 in participants with advance solid tumor cancer that has a KRAS, HRAS, or NRAS G12D mutation.
What is the current status of trial NCT07638371?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2026-06-09. Estimated completion is 2030-06-09.
What interventions are being tested in trial NCT07638371?
The interventions under investigation include: MSK-TCR5 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07638371?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.